This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Cerevel Therapeutics Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Cerevel Therapeutics Holdings' CEO is Ron Renaud, appointed in Jun 2023, has a tenure of 1.17 years. total yearly compensation is $32.32M, comprised of 1.2% salary and 98.8% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $10.98M. The average tenure of the management team and the board of directors is 3.7 years and 5.4 years respectively.

Anahtar bilgiler

Ron Renaud

İcra Kurulu Başkanı

US$32.3m

Toplam tazminat

CEO maaş yüzdesi	1.2%
CEO görev süresi	1.2yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	3.7yrs
Yönetim Kurulu ortalama görev süresi	5.4yrs

Son yönetim güncellemeleri

Recent updates

Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Apr 30

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Jan 02

Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded

Jul 08

Cerevel Therapeutics: Pfizer's Neurology Spin-Off

Jul 14

We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Jun 09

Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Jan 29

Cerevel Therapeutics (CERE) Investor Presentation - Slideshow

Nov 18

Cerevel Therapeutics reports Q3 results

Nov 16

CEO Tazminat Analizi

Ron Renaud'un ücretlendirmesi Cerevel Therapeutics Holdings'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2024	n/a	n/a	-US$460m
Dec 31 2023	US$32m	US$375k	-US$433m

Tazminat ve Piyasa: Ron's total compensation ($USD32.32M) is above average for companies of similar size in the US market ($USD8.50M).

Tazminat ve Kazançlar: Insufficient data to compare Ron's compensation with company performance.

CEO

Ron Renaud (55 yo)

1.2yrs

Görev süresi

US$32,322,358

Tazminat

Mr. Ronald C. Renaud, also known as Ron, Jr., M.B.A., serves as President, CEO & Director at Cerevel Therapeutics Holdings, Inc. since June 12, 2023. He served as Managing Director at Bain Capital Life Sci...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
N. Coles	Executive Chairman	5.8yrs	US$31.98m	0.0086% $ 702.8k
Ronald Renaud	President	1.2yrs	US$32.32m	0.13% $ 11.0m
Susan Altschuller	Chief Financial Officer	1.3yrs	US$4.63m	0.0093% $ 760.2k
Mark Bodenrader	Senior VP of Finance & Chief Accounting Officer	4.9yrs	US$1.21m	0.0097% $ 797.0k
John Renger	Chief Scientific Officer	5.3yrs	US$3.45m	0.0035% $ 286.7k
Ramiro Sanchez	Chief Medical Officer	5.6yrs	US$4.13m	0.0080% $ 659.4k
Paul Burgess	Chief Business Development & Strategic Operations Officer	1.2yrs	US$3.55m	0.025% $ 2.1m
Matthew Calistri	Vice President of Investor Relations	no data	Veri yok	Veri yok
Scott Akamine	Chief Legal Officer & Corporate Secretary	3.3yrs	US$3.19m	0.0040% $ 325.2k
Kenneth DiPietro	Chief Human Resources Officer	5.3yrs	Veri yok	0.014% $ 1.1m
Kathleen Tregoning	Chief Corporate Affairs Officer & Head of Commercial Strategy	4.1yrs	US$3.92m	0.0059% $ 479.2k

3.7yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: CERE's management team is considered experienced (3.7 years average tenure).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
N. Coles	Executive Chairman	5.8yrs	US$31.98m	0.0086% $ 702.8k
Ronald Renaud	President	1.2yrs	US$32.32m	0.13% $ 11.0m
Gabrielle Greene-Sulzberger	Independent Director	5.2yrs	US$513.93k	0.027% $ 2.2m
Marijn Dekkers	Independent Director	5.9yrs	US$486.49k	0.017% $ 1.4m
Deval Patrick	Independent Director	3.6yrs	US$485.48k	0.0018% $ 147.4k
Norbert Riedel	Lead Independent Director	5.7yrs	US$564.65k	0.025% $ 2.1m
Christopher Gordon	Independent Director	5.9yrs	US$501.43k	0.0018% $ 147.4k
Adam Koppel	Independent Director	5.9yrs	US$504.65k	0.0018% $ 147.4k
Douglas Giordano	Independent Director	5.9yrs	US$505.21k	0.0018% $ 147.4k
Ruth McKernan	Independent Director	3.7yrs	US$485.48k	0% $ 0
Suneet Varma	Independent Director	2.2yrs	Veri yok	Veri yok
Deborah Baron	Independent Director	3.6yrs	Veri yok	Veri yok

5.4yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CERE's board of directors are considered experienced (5.4 years average tenure).

This company has been acquired

Cerevel Therapeutics Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Recent updates

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Price target increased by 9.7% to US$36.60

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) for $8.2 billion.

Independent Director notifies of intention to sell stock

Cerevel Therapeutics Holdings, Inc. to Report Q3, 2023 Results on Nov 01, 2023

New minor risk - Shareholder dilution

Cerevel Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $449.999991 million.

Cerevel Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $449.999991 million.

Executive Chairman notifies of intention to sell stock

President recently bought US$2.0m worth of stock

Price target decreased by 8.1% to US$34.13

Price target decreased by 7.4% to US$34.38

Executive Chairman notifies of intention to sell stock

Cerevel Therapeutics Holdings, Inc. to Report Q2, 2023 Results on Aug 02, 2023

High number of new directors

Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer, Effective from June 20, 2023

Executive Chairman & CEO notifies of intention to sell stock

Cerevel Therapeutics Appoints Susan Altschuller as Chief Financial Officer

Executive Chairman & CEO notifies of intention to sell stock

Cerevel Therapeutics Holdings, Inc. Announces Executive Changes

Price target decreased by 8.8% to US$35.20

Executive Chairman & CEO notifies of intention to sell stock

Price target decreased by 9.3% to US$37.09

Executive Chairman & CEO notifies of intention to sell stock

Executive Chairman & CEO exercised options and sold US$1.5m worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Executive Chairman & CEO exercised options and sold US$1.3m worth of stock

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Executive Chairman & CEO exercised options and sold US$1.2m worth of stock

Chief Scientific Officer exercised options and sold US$561k worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chief Scientific Officer exercised options and sold US$561k worth of stock

Cerevel overweight at Wells Fargo due to candidates with blockbuster potential

Price target increased to US$43.29

President exercised options and sold US$371k worth of stock

President exercised options and sold US$186k worth of stock

Cerevel Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $253.75 million.

Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering

President notifies of intention to sell stock

Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13

Cerevel Therapeutics Holdings, Inc. to Report Q2, 2022 Results on Aug 01, 2022

Chief Scientific Officer exercised options and sold US$663k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded

Price target decreased to US$39.71

Cerevel Therapeutics Appoints Suneet Varma to Serve as Member of Its Board of Directors

Chief Scientific Officer exercised options and sold US$1.4m worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q1, 2022 Results on May 10, 2022

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$1.2m worth of stock

Chief Scientific Officer exercised options and sold US$895k worth of stock

Chief Scientific Officer exercised options and sold US$663k worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety

Chief Scientific Officer exercised options and sold US$663k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Price target increased to US$46.33

Price target decreased to US$32.67

Price target increased to US$36.33